- Home
- OMCC vs BIVI Comparison
OMCC vs BIVI Comparison
Compare OMCC & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCC
- BIVI
- Stock Information
- Founded
- OMCC 1985
- BIVI 2013
- Country
- OMCC United States
- BIVI United States
- Employees
- OMCC N/A
- BIVI N/A
- Industry
- OMCC
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- OMCC
- BIVI Health Care
- Exchange
- OMCC NYSE
- BIVI Nasdaq
- Market Cap
- OMCC 43.4M
- BIVI 49.8M
- IPO Year
- OMCC N/A
- BIVI N/A
- Fundamental
- Price
- OMCC $6.05
- BIVI $1.90
- Analyst Decision
- OMCC
- BIVI Strong Buy
- Analyst Count
- OMCC 0
- BIVI 1
- Target Price
- OMCC N/A
- BIVI $30.00
- AVG Volume (30 Days)
- OMCC 17.8K
- BIVI 1.5M
- Earning Date
- OMCC 02-11-2025
- BIVI 02-11-2025
- Dividend Yield
- OMCC N/A
- BIVI N/A
- EPS Growth
- OMCC N/A
- BIVI N/A
- EPS
- OMCC N/A
- BIVI N/A
- Revenue
- OMCC $22,181,000.00
- BIVI N/A
- Revenue This Year
- OMCC N/A
- BIVI N/A
- Revenue Next Year
- OMCC N/A
- BIVI N/A
- P/E Ratio
- OMCC N/A
- BIVI N/A
- Revenue Growth
- OMCC N/A
- BIVI N/A
- 52 Week Low
- OMCC $5.29
- BIVI $1.04
- 52 Week High
- OMCC $7.55
- BIVI $33.10
- Technical
- Relative Strength Index (RSI)
- OMCC N/A
- BIVI 30.38
- Support Level
- OMCC N/A
- BIVI $2.41
- Resistance Level
- OMCC N/A
- BIVI $2.70
- Average True Range (ATR)
- OMCC 0.00
- BIVI 0.23
- MACD
- OMCC 0.00
- BIVI -0.12
- Stochastic Oscillator
- OMCC 0.00
- BIVI 0.00
About OMCC OLD MARKET CAPITAL CORPORATION
Old Market Capital Corp formerly Nicholas Financial Inc is a specialized consumer finance company. It is engaged in acquiring and servicing automobile finance installment contracts for purchases of used and new automobiles and light trucks. It also originates direct consumer loans and sells consumer-finance-related products. The majority of its revenue comes from Interest and fee income.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.